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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the beneficial and harmful effects of pre-exposure hepatitis A vaccines (inactivated and live-attenuated) administered to adults
and children versus no intervention, placebo, or any other vaccine.
Hepatitis A immunisation in persons not previously exposed to hepatitis A (Protocol)









Cochrane Database of Systematic Reviews
B A C K G R O U N D
Hepatitis A infection is caused by the hepatitis A virus (HAV). He-
patitis A is transmitted through contact with infectious persons
as well as through foodborne and waterborne transmission routes
(WHO 2016). Poor hygiene and sanitation pose the greatest risk re-
lated to HAV infection in low- and middle-income regions (de Jong
2007). In high-income regions, at-risk groups include those partici-
pating in anal sex, injection drug users, day-care employees or fam-
ilies of children in day care, and consumers of high-risk foods (e.g.
raw shellfish) (Heathcote 2012). The epidemiology of hepatitis A is
largely driven by socioeconomic indicators including economic de-
velopment, sanitation, and access to clean water (WHO 2012; Ott
2013).
Infection with HAV early in life usually leads to asymptomatic dis-
ease and development of long-lasting immunity through IgG sero-
conversion (de Jong 2007). Levels of HAV endemicity are based on
the proportion of those who are IgG positive in a population (Nel-
son 2006). The World Health Organization (WHO) describes the lev-
els of endemicity on the basis of seroprevalence as: high (≥ 90% by
age 10 years); intermediate (≥ 50% by age 15 years, with < 90% by
age 10 years); low (≥ 50% by age 30 years, with < 50% by age 15);
and very low (< 50% by age 30 years) (WHO 2012). As a result of ear-
ly life HAV infections in high endemicity settings, there are few sus-
ceptible adolescents and adults in these populations. Intermediate
HAV endemicity is often observed in regions with developing urban
populations where IgG seroprevalence is often mixed. Low HAV en-
demicity is observed in high-income settings where circulation of
HAV and IgG seropositivity in the population are both low. In these
setting, a majority of the population is susceptible to HAV; howev-
er, the risk of infection remains low as the virus rarely circulates.
Description of the condition
Once infection occurs, HAV is replicated in the liver and excreted
in the bile and stools of infected persons (WHO 2012). The peak of
virus excretion occurs two weeks before the onset of hepatitis A
symptoms and the incubation period is approximately 28 days (de
Jong 2007). Following infection with HAV, five clinical patterns are
possible: asymptomatic infection; symptomatic infection; relaps-
ing hepatitis A; cholestasis hepatitis A; and fulminant hepatitis A
(Lemon 2017). Hepatitis A symptoms are strongly correlated with
age and clinical severity increases as infected individuals get older
(Rajan 2000; de Jong 2007; Ellis 2007). Chronic infection with HAV
does not occur as infection with HAV resolves spontaneously and
leads to development of immunity through IgG anti-HAV antibodies
8 to 12 weeks after initial infection (de Jong 2007; Heathcote 2012).
Symptoms of HAV infection most commonly include a loss of
appetite, fatigue, upper-right-quadrant abdominal pain, nausea,
vomiting, jaundice, dark urine, and fever (de Jong 2007; Lemon
2017). The fatality rate associated with hepatitis A in children and
adults under 50 years old ranges from 0.3% to 0.6%, while fatali-
ty rates in adults aged 50 years or older range from 1.8% to 5.4%
(Lemon 2017). Complications of hepatitis A include cholestasis, re-
lapsing hepatitis A, and fulminant hepatic failure. Cholestatic he-
patitis A develops when bile flow is decreased due to impaired se-
cretion by hepatocytes or blocked bile ducts. Relapsing hepatitis A
involves relapse of symptoms and abnormal liver function one to
four months after initial symptoms have resolved (Glickson 1992;
de Jong 2007). This is uncommon and occurs in approximately 3%
to 20% of infected individuals (Glickson 1992). Fulminant hepatic
failure is rare but serious, occurring in approximately 0.01% of in-
fected individuals, in which extensive liver damage occurs within
the first six to eight weeks of HAV infection (de Jong 2007; Heath-
cote 2012). Mortality rates associated with fulminant hepatic failure
range from 70% to 95% (KoH 1998; de Jong 2007; Heathcote 2012).
Management for acute hepatitis A is generally supportive (Heath-
cote 2012). Abstinence from alcohol is often advised during HAV
infection (Heathcote 2012). Nausea and vomiting are treated with
antiemetics; and acetaminophen may be administered to adults
but is restricted at a maximum of 4 g per day (Gilroy 2019). Dehy-
dration may be managed with hospital admission and administra-
tion of intravenous fluids.
Description of the intervention
Pre-exposure prophylaxis for hepatitis A includes vaccination.
There are currently two types of hepatitis A vaccine available: inac-
tivated vaccines; and live-attenuated vaccines (WHO 2012). Inacti-
vated hepatitis A vaccines are licensed for use globally in adults and
children aged 12 months or older. There are currently five differ-
ent inactivated hepatitis A vaccines on the market (Avaxim(R), Epax-
al(R), Havrix(R), Healive(R) and Vaqta(R)), each requiring two doses
to be administered within 6 to 12 months of each other (WHO 2012).
Havrix(R) and Healive(R) are both WHO pre-qualified vaccines for
the prevention of hepatitis A (WHO 2012). Within two to four weeks
of the first dose of inactivated hepatitis A, up to 100% of children
and young adults achieve seroconversion (WHO 2012). Some stud-
ies further indicate that inactivated hepatitis A vaccines are pro-
tective after a single dose (Iwarson 2004; WHO 2012; Ott 2013). In-
activated hepatitis A vaccines can be prepared as a single antigen
vaccine or combined with hepatitis B recombinant antigens or ty-
phoid (Proell 2002). Inactivated hepatitis A vaccines have a widely
accepted safety profile with no reports of serious adverse events
(Bryan 2001; Ott 2012; Rao 2016). The most frequently reported
adverse events associated with inactivated hepatitis A are injec-
tion-site pain, headache, and general malaise (Wasley 2006).
Live-attenuated hepatitis A vaccines are manufactured in China
and licensed for use in several other countries (WHO 2012). Live-at-
tenuated vaccines are administered in a single-dose schedule. Pre-
vious systematic reviews have concluded that significant protec-
tion is offered by both live-attenuated and inactivated hepatitis A
vaccines and both inactivated and live-attenuated hepatitis A vac-
cines are capable of providing protection for up to 15 years (Van
Herck 2004). Quality vaccine safety data are, however, lacking to
adequately compare the safety profiles of the two types of hepati-
tis A vaccines (Demicheli 2003; WHO 2012). The cost effectiveness
of hepatitis A vaccination in low endemicity settings is well docu-
mented, with high coverage being most cost effective in areas with
high hepatitis A incidence (Anonychuck 2008; WHO 2012).
Other methods of primary hepatitis A prevention include adequate
sanitation, frequent hand washing, and access to safe food and wa-
ter (de Jong 2007). Post-exposure prophylaxis (PEP) against HAV
infections includes administration of human immune globulin (IG)
(Liu 2009). Post-exposure prophylaxis is 80% to 90% effective when
administered no more than 14 days after HAV exposure (Liu 2009;
Lemon 2017). It may prevent hepatitis A symptoms and liver dis-
ease but in most cases does not prevent HAV infection (Lemon
2017).
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How the intervention might work
Vaccination with hepatitis A vaccines results in the induction of
anti-HAV antibodies (IgG), inducing both cellular and humoral im-
mune memory (Van Damme 1994). The vaccine-induced anti-HAV
antibodies bind to and neutralise HAV upon infection (Flehmig
1997). Detectable anti-HAV antibody titre levels of 10 mIU/mL or
more are used as a correlate of protective immunity (Purcell 1992;
Flehmig 1997; Wasley 2006). Inactivated HAV vaccines have been
documented to generate antibody responses that persist for up to
20 years and have been modelled to persist for an additional 20
years (WHO 2012; Van Damme 2017). Immune memory responses
to live-attenuated HAV vaccines are not as well documented. Lim-
ited studies have been performed which indicate that inactivated
hepatitis A vaccines are safe and immunogenic for patients living
with HIV, although patients with lower CD4 T-cell counts are more
likely to be non-responders than those with higher counts (Mena
2015).
Why it is important to do this review
A systematic review with meta-analysis of randomised clinical trials
published in 2003 aimed to assess the efficacy and safety of inacti-
vated hepatitis A vaccines (Demicheli 2003). The review determined
inactivated hepatitis A vaccines to be effective in the prevention of
hepatitis A infections, but it did not assess the efficacy or safety of
live-attenuated vaccines. In 2012, a Cochrane Review with meta-
analysis of randomised clinical trials aimed to compare the efficacy
and safety of inactivated and live-attenuated hepatitis A vaccines
(Irving 2011; Irving 2012). The review concluded that both vaccine
types provide significant protective effects against hepatitis A, but
it was unable to adequately compare the safety profiles of the two
vaccine types as it included a limited number of comparative stud-
ies with data on adverse events following immunisation.
Our aim is to update the Irving 2012 Cochrane Review that assessed
the efficacy and safety profiles of inactivated and live-attenuated
hepatitis A. We will try to generate comparable safety profiles of the
two types of hepatitis A vaccines by including a number of vaccine
trials not included in the original 2012 review. It is important to gen-
erate comparable safety profiles of the two types of hepatitis A vac-
cines: the vaccine safety profile is a primary concern in the admin-
istration of vaccines in both clinical practice and in development of
evidence-based vaccine recommendations.
We will also assess the duration of protection offered by single and
multiple doses of inactivated and live-attenuated hepatitis A vac-
cines to inform the current debate on the optimal number of inacti-
vated hepatitis A doses needed to prevent the disease (Van Damme
2003; WHO 2012; Ott 2013; Lim 2014).
O B J E C T I V E S
To assess the beneficial and harmful effects of pre-exposure he-
patitis A vaccines (inactivated and live-attenuated) administered to
adults and children versus no intervention, placebo, or any other
vaccine.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials irrespective of blinding,
publication date, and language.
Types of participants
We will include adults and children aged 12 months or older of ei-
ther sex and any country of residence and not previously exposed
to hepatitis A. We define pre-exposure status as lack of anti-HAV IgG
antibodies (Lemon 2017).
Types of interventions
• Any type of inactivated or live-attenuated hepatitis A vaccine
(experimental intervention) versus placebo or no intervention
(control intervention).
• Any type of inactivated or live-attenuated hepatitis A vaccine
(experimental intervention) versus any vaccine other than HAV
vaccine (control intervention).
• One type of inactivated or live-attenuated hepatitis A vaccine
(experimental intervention) versus another type of inactivated
or live-attenuated hepatitis A vaccine (control intervention).
Types of outcome measures
Primary outcomes
• All-cause mortality.
• Proportion of participants with confirmed hepatitis A infection
(that is, alanine transaminase (ALT) levels 2 to 3 times higher
than normal limit ≦ 43 mIU/L) (Kim 2008) and/or laboratory con-
firmed hepatitis A infection (Immunoglobulin M-HAV (IgM-HAV)).
• Proportion of participants with one or more serious adverse
events following immunisation with hepatitis A vaccines. A se-
rious adverse event is defined as any untoward medical occur-
rence that at any dose: results in death; is life-threatening; re-
quires hospitalisation or prolongation of existing hospitalisa-
tion; results in persistent or significant disability/incapacity; or
is a congenital anomaly/birth defect (ICH-GCP 1997).
Secondary outcomes
• Hepatitis A-specific mortality.
• Health-related quality of life.
• Proportion of participants with adverse events considered to be
non-serious following immunisation with hepatitis A vaccines.
• Proportion of participants with anti-HAV antibody titre levels ≧
10 mIU/mL at the last study day available following vaccination
(Wiedermann 1992; WHO 2012).
We will collect data for all time periods reported in the included
studies and, if possible, we will define them into groups. We will
consider the longest follow-up as our primary analysis of the out-
come data. We will analyse data for all outcomes following the ad-
ministration of one, two, and three doses of hepatitis A vaccines.
We will allow co-interventions if administered equally to the exper-
imental and control groups of the trial.
Hepatitis A immunisation in persons not previously exposed to hepatitis A (Protocol)
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Search methods for identification of studies
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled Tri-
als Register (maintained and searched internally by the CHBG In-
formation Specialist via the Cochrane Register of Studies ‒ Web),
the Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library (latest issue), MEDLINE Ovid (1946 to date of
search), Embase Ovid (1974 to date of search), LILACS (1982 to date
of search; Bireme), Science Citation Index Expanded (1900 to the
date of search; Web of Science), and Conference Proceedings Cita-
tion Index ‒ Science (1990 to the date of search; Web of Science)
(Royle 2003). Appendix 1 gives the preliminary search strategies
with the expected time spans.
We will also endeavour to identify non-English randomised clini-
cal trials references using the following databases: the China Na-
tional Knowledge Infrastructure (CNKI); the Chinese Scientific Jour-
nals database (CSJD-VIP); the China Science Periodical Database
(CSPD); Wanfang Data (www.wanfangdata.com.cn); the Russian
Federation Clinical Trials Register (CenterWatch); the Latin Ameri-
can Ongoing Clinical Trial Register (LATINREC); the Indonesian Clin-
ical Trials Registry; and the European Clinical Trials Register (Eu-
draCT). We will also use our personal contacts, local access and/
or refer to the Cochrane Hepato-Biliary Group (CHBG) Informa-
tion Specialist to contact Cochrane collaborators from around the
world with the intent of finding relevant non-English randomised
clinical trials.
Searching other resources
We will conduct additional searches for eligible randomised trials
by cross-checking the reference list of published randomised clini-
cal trials and systematic reviews.
We will search on-line trial registries such as ClinicalTrials.gov, Eu-
ropean Medicines Agency (EMA) (www.ema.europa.eu/ema), WHO
International Clinical Trial Registry Platform (www.who.int/ictrp),
and the Food and Drug Administration (FDA) (www.fda.gov), as well
as pharmaceutical company sources, for ongoing or unpublished
trials. We will also search for grey literature in the System for In-
formation on Grey Literature in Europe “OpenGrey” (www.open-
grey.eu).
Data collection and analysis
Selection of studies
Two authors, Jenna Patterson (JP) and Helen Mearns (HM), will in-
dependently screen all titles and abstracts for inclusion of poten-
tially eligible randomised trials sourced from non-Chinese databas-
es. Yu Qi Li (YQL) and Yue Jiang (YJ) will screen all titles and abstracts
sourced from the Chinese databases we search. JP, HM, YQL, and YJ
will collect full-text trial reports/publications of potentially eligible
studies and independently screen them for inclusion. Trials report-
ing one or more of the primary outcomes will be eligible for inclu-
sion in this review. The authors will consult Greg Irving (GI) when
they cannot agree on eligibility. We will record the selection process
with reasons for exclusion using a PRISMA flow diagram.
If, during the selection of trials, we identify observational studies
such as quasi-randomised or controlled clinical studies with the
same characteristics of participants and interventions as in our pro-
tocol and reporting adverse events relevant to the outcomes of this
review, then we will extract the adverse event data in their experi-
mental and control groups separately from the data from the ran-
domised clinical trials. We will not specifically search for observa-
tional studies for inclusion in this review, which is a known limita-
tion of the study in terms of adverse events. We are aware that the
decision not to search systematically for all observational studies
as well as extracting data on harm only from quasi-randomised and
controlled clinical studies might bias our review towards assess-
ment of benefits and might overlook certain harms such as late or
rare harms. If we demonstrate benefits from using hepatitis A vac-
cines in persons not previously exposed to hepatitis A, then a sys-
tematic review of the harms of hepatitis A vaccines in persons not
previously exposed to hepatitis A in observational studies ought to
be launched (Storebø 2018).
Data extraction and management
Two authors (JP and HM) will independently extract data from the
included non-Chinese trials. YQL and YJ will extract data from all
Chinese trials included in the review. In the event of any disagree-
ment between the authors, they will consult GI.
We will seek data on all participants, irrespective of compliance or
follow-up, to allow intention-to-treat analyses. In cases where trials
have cross-over designs, we will consider data from only the first
period. We will identify trials by the name of the first author and the
year of publication.
We will collect the following data; and where sufficient data ex-
ist, we will perform subgroup analyses according to the Subgroup
analysis and investigation of heterogeneity section.
• Characteristics of the trial: date, trial registration number, sam-
ple size, HAV endemicity setting, generation of allocation se-
quence, allocation concealment method, blinding methods and
other information following the definitions of the bias risk do-
mains (see below).
• Characteristics of the participants: number of participants in
each group, age, sex, nationality, ethnic group, presence of
known HAV infection risk factors (including injection drug users,
living in poor socioeconomic areas, and poor access to clean
water and sanitation facilities), presence of immunodeficiency,
baseline comparability from trial demographic information.
• Characteristics of the intervention: type of vaccine, type of con-
trol, number of doses administered, immunisation schedule,
route of administration.
• Characteristics of outcomes measures as presented in the trial
publications (these will be presented in the 'Characteristics of
included studies' table) and following our review outcomes: pri-
mary and secondary outcomes, type of antibody test used, ad-
verse events, length of follow-up, and loss to follow-up before
the end of trial.
Where any predefined outcome is not reported, we will contact the
investigators or study sponsors to ask for the reason.
Assessment of risk of bias in included studies
We will follow the instructions given in the Cochrane Handbook
for Systematic Reviews of Interventions to assess the risk of bias of
each included clinical trial (Higgins 2019). We will assess the risk of
bias of trials on the basis of the domains described in the follow-
ing sections of the review and provide reasons for judgement in a
Hepatitis A immunisation in persons not previously exposed to hepatitis A (Protocol)
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‘Risk of bias’ table for each bias domain (Schulz 1995; Moher 1998;
Kjaergard 2001; Wood 2008; Savović 2012a; Savović 2012b; Savović
2018). We will create ‘Risk of bias’ plots in Review Manager 5 (Re-
view Manager 2014).
Sequence generation
• Low risk of bias: the study authors performed sequence gener-
ation using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice are adequate if an independent person not oth-
erwise involved in the study performed them. If block randomi-
sation was used, we will consider it adequate if a computer ran-
dom number generator was used for selection of random per-
muted blocks for the randomisation list of the participants. We
will judge if the block randomisation was adequate also by look-
ing into the details of the block randomisation regarding ratio,
size, and stratification of the block randomisation.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not ran-
dom or only quasi-randomised. ‘Herd effect’ or recruitment bias
in the cluster-randomised clinical trials appears likely. We will
only include such studies for assessment of harm.
Allocation concealment
• Low risk of bias: the participant allocations could not have been
foreseen in advance of, or during, enrolment. The investigators
were unaware of the allocation sequence. A central and inde-
pendent randomisation unit was used to control allocation or
sealed envelopes allocating drug assignments were prepared by
an independent pharmacist.
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention allo-
cations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who assigned
the participants knew the allocation sequence. We will only in-
clude such studies for assessment of harm.
Blinding of participants and personnel
• Low risk of bias: blinding of participants, healthcare workers and
key study personnel was ensured until completion of the study.
It is unlikely that the blinding could have been broken given the
methods described.
• Unclear: insufficient information to permit judgement of ‘low
risk’ or ‘high risk’ or the trial did not address blinding.
• High risk of bias: the trial was not blinded to participants, health-
care workers and key study personnel. It is likely that the blind-
ing could have been broken given the methods described.
Blinding of outcome assessment
• Low risk of bias: blinding of outcome assessment was ensured
until completion of the study analysis. It is unlikely that the
blinding could have been broken given the methods described.
• Unclear risk of bias: insufficient information to permit judge-
ment of ‘low risk’ or ‘high risk’ or the trial did not address blind-
ing of outcome assessment.
• High risk of bias: no blinding of outcome assessment took place
or the outcome measurement was likely to be influenced by lack
of blinding, or both.
Incomplete outcome data reporting
• Low risk of bias: missing data were unlikely to make treatment
effects depart from plausible values. The study used sufficient
methods, such as multiple imputation, to handle missing da-
ta. Data for all individuals within clusters or all clusters in clus-
ter-randomised clinical trials are reported.
• Unclear risk of bias: there was insufficient information to assess
whether missing data in combination with the method used to
handle missing data were likely to bias the results. Data for one
or more individuals or clusters in cluster-randomised clinical tri-
als are missing.
• High risk of bias: the results were likely to be biased due to miss-
ing data.
Selective outcome reporting
• Low risk of bias: if the original trial protocol was available, the
outcomes reported should have been those called for in the pro-
tocol. If we obtained the trial protocol from a trial registry, the
outcomes sought should have been those enumerated in the
original protocol if the trial protocol was registered before or
at the time the trial was begun. If the trial protocol was regis-
tered after the beginning of the trial, we will not consider those
outcomes to be reliable. The trial reported the following prede-
fined outcomes with at least one of the outcomes related to the
main reason of prevention of hepatitis A through immunisation,
namely:
* proportion of participants with all-cause mortality
* proportion of participants with hepatitis-A-specific mortality
* proportion of participants with clinically confirmed hepatitis
A infection
* proportion of participants with serious adverse events fol-
lowing immunisation with hepatitis A vaccines
* proportion of participants with non-serious adverse events
following immunisation with hepatitis A vaccines
* proportion of participants responding to hepatitis A immuni-
sation
• Unclear risk of bias: not all predefined or clinically relevant and
reasonably expected outcomes were reported fully or it was un-
clear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically relevant
and reasonably expected outcomes were not reported, despite
the fact that data on these outcomes should have been available
and even recorded.
Overall bias assessment
We will assess overall risk of bias in each trial as:
• low risk of bias, if we have assessed all domains in a trial at low
risk of bias; or
• high risk of bias, if we have assessed one or more of the domains
in a trial at unclear or high risk of bias.
Measures of treatment e8ect
We will use the statistical package Review Manger 5 provided by
Cochrane for statistical analyses (Review Manager 2014). We plan
to present dichotomous outcome data as risk ratios (RRs) with 95%
confidence intervals (CIs). We plan to present continuous outcome
data as mean difference (MD) if all studies reported their outcomes
using the same scale, and as standardised mean difference (SMD) if
Hepatitis A immunisation in persons not previously exposed to hepatitis A (Protocol)
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the studies used different scales to report their outcomes. We will
use 95% confidence intervals (CIs). We will re-express calculated
SMD using the rule of thumb where Cohen's d = 0.2 will be consid-
ered a 'small' effect size, 0.5 represents a 'medium' effect size, and
0.8 a 'large' effect size (Cohen 1988). For time-to-event data, we will
calculate hazard ratio (HR) with 95% CI.
Unit of analysis issues
The unit of analysis will be the individual trial participant in the ex-
perimental or control group of the included trial to which the par-
ticipant was randomly assigned.
Cluster-randomised clinical trials
For cluster-randomised clinical trials that have used correct statis-
tical methods regarding clustering, we will use the generic inverse
variance approach to analyse effect estimates and their standard
errors. If incorrect statistical methods regarding clustering were
used, we will implement methods for correcting trial results ac-
cording to the Cochrane Handbook for Systematic Reviews of Inter-
ventions Section 16.3.6 (Higgins 2019).
Trials with more than two intervention groups (multi-group
trials)
In case of multi-group trials, we will analyse multiple intervention
groups in a way that would avoid arbitrary omission of relevant
groups and double-counting of participants. We will only extract
data from the trial groups that correspond to the interventions be-
ing considered for this review. In case of two experimental inter-
vention groups of interest to our review and only one common con-
trol group, we will divide the control group into two to avoid dou-
ble-counting while adding data to the review meta-analysis.
We do not expect trials with a cross-over design.
Dealing with missing data
We will perform our analyses based on the intention-to-treat prin-
ciple whenever possible, including all randomly assigned partici-
pants, irrespective of completeness of data. We will contact inves-
tigators or study sponsors if data are missing. In the event of no re-
ply within six months, we will impute a replacement value for the
missing data in sensitivity analyses according to the following two
extreme case scenarios for our primary outcomes (Hollis 1999).
• Extreme case analysis favouring the experimental intervention
('best-worst' case scenario): none of the dropouts/participants
lost from the experimental arm but all of the dropouts/partic-
ipants lost from the control arm experienced the outcome, in-
cluding all randomised participants in the denominator.
• Extreme case analysis favouring the control ('worst-best' case
scenario): all dropouts/participants lost from the experimental
arm but none from the control arm experienced the outcome,
including all randomised participants in the denominator.
We will report the impact of any missing data on our findings.
Assessment of heterogeneity
We will first document the variability in the participants, interven-
tions, and outcomes in the included trials to assess clinical hetero-
geneity. Then we will document the variability in study design and
risk of bias of the included trials to assess methodological hetero-
geneity.
We will use forest plots to graphically assess statistical heterogene-
ity in the intervention effects (Review Manager 2014; Higgins 2019).
We will calculate Chi2 values and I2 statistics to statistically measure
the presence of heterogeneity. The Chi2 threshold for presence of
heterogeneity is P less than 0.1 and the I2 statistic threshold is I2
greater than 40%. The values of the I2 statistic for heterogeneity are
defined in the Cochrane Handbook for Systematic Reviews of Inter-
ventions as follows: not important (0% to 40%); moderate (41% to
60%); substantial (61% to 80%); and considerable (81% to 100%).
Assessment of reporting biases
We will use funnel plots if there are 10 or more trials included per
comparison. Symmetry or asymmetry of each funnel plot enables
visual assessment of whether treatment estimates are associated
with trial size. We will use the Egger test to test for the funnel plot
symmetry (Egger 1997).
Data synthesis
We will conduct this systematic review according to the recommen-
dations stated in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2019).
We will perform statistical analyses according to the statistical
guidelines referenced in theCochrane Handbook for Systematic Re-
views of Interventions (Higgins 2019).
For the statistical analyses we will use Review Manager 5 (Review
Manager 2014). We will analyse the data using the random-effects
model meta-analyses (DerSimonian 1986). For dichotomous out-
comes, we will calculate risk ratios (RRs) and for continuous out-
comes such as health-related quality of life, we will calculate mean
difference (MD) or standardised mean difference (SMD). For all as-
sociation measures, we will use 95% CIs.
We will incorporate data from cluster-randomised trials using the
Mantel-Haenszel and generic inverse variance method (Higgins
2019).
We will present the data on adverse events from the included qua-
si-randomised and controlled clinical studies in a tabular or narra-
tive format (Loke 2007).
Subgroup analysis and investigation of heterogeneity
We will perform the following subgroup analyses to further explore
heterogeneity.
• Vaccines type: inactivated compared to live-attenuated
* It is important to the objectives of the review to separate vac-
cine types in the review analysis.
• Number of vaccine doses: single dose compared to multiple dos-
es
* It is important to the objectives of the review to separate vac-
cine doses in the review analysis. Length of follow-up: 1 to
12 months compared to 13 to 24 months compared to 25 to
36 months compared to 37 to 48 months, compared to 49
months or more. It is important to understand the duration of
immunity to separate follow-up times in the review analysis.
Hepatitis A immunisation in persons not previously exposed to hepatitis A (Protocol)
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• Proportion of participants with long-term persistence of an-
ti-HAV antibody titre levels ≧ 10 mIU/mL following administra-
tion of a single or multiple dose(s) of hepatitis A vaccine
* It is important to the objectives of the review to separate the
long-term persistence of anti-HAV antibody titre levels by the
number of vaccine doses administered.
Sensitivity analysis
In addition to the sensitivity analysis aiming to explore how imput-
ed values impact the robustness of outcome estimates (see Dealing
with missing data), we will perform the following sensitivity analy-
ses to explore the impact of trial size and risk of bias.
• We will remove cluster-randomised trials from outcome analy-
ses to explore their impact of bias on the robustness of outcome
estimates.
• We will remove trials with vested interests to explore their im-
pact of bias on the robustness of outcome estimates.
• We will remove small trials (those providing less than 10%
weight to the analysis) from outcome analyses to explore their
impact of the robustness of outcome estimates.
• We will remove trials judged to have an overall ‘high’ risk of bias
from outcome analyses to explore their impact of bias on the ro-
bustness of outcome estimates.
We will also compare our GRADE imprecision assessments for out-
comes listed below to those assessed with Trial Sequential Analysis
(Jakobsen 2014).
• All-cause mortality.
• Proportion of participants with clinically confirmed hepatitis A
infection (alanine transaminase (ALT) levels 2 to 3 times higher
than normal limit ≦ 43 mIU/L), and/or laboratory confirmed he-
patitis A infection (Immunoglobulin M-HAV (IgM-HAV)).
• Proportion of participants with one or more serious adverse
events following immunisation with hepatitis A vaccines.
• Proportion of participants with adverse events considered to be
non-serious, following immunisation with hepatitis A vaccines.
• Proportion of participants with anti-HAV antibody titre levels ≧
10 mIU/mL at the last study day available following vaccination.
Trial Sequential Analysis
Trial Sequential Analysis is a statistical method which controls the
risk of random error caused by sparse data and formal or informal
repetitive testing of accumulating data (Thorlund 2011; TSA 2011;
Wetterslev 2017). When a few small trials are combined in a meta-
analysis, the risk of introducing random errors increases due to
sparse data and due to multiplicity when conducting cumulative
meta-analyses. We will employ Trial Sequential Analysis to control
the risk of random errors for the primary outcomes including all-
cause mortality and occurrence of hepatitis A and serious adverse
events (Brok 2008; Wetterslev 2008; Brok 2009; Thorlund 2009; Wet-
terslev 2009; Thorlund 2010; Thorlund 2011; TSA 2011; Wetterslev
2017). We will estimate the required information size based on the
proportion of participants with an outcome in the control group, a
relative risk reduction of 20%, an alpha of 2.5% because of three
primary dichotomous outcome assessments and 2.0% because of
four secondary outcomes, a beta of 10%, and the observed diver-
sity in the trials in the meta-analysis (Jakobsen 2014; Wetterslev
2017). We will add the trials according to the year of publication,
and if more than one trial has been published in a year, we will add
trials alphabetically according to the last name of the first author.
On the basis of the required information size we will construct tri-
al sequential monitoring boundaries (Brok 2008; Wetterslev 2008;
Brok 2009; Thorlund 2009, Wetterslev 2009; Thorlund 2010; Wetter-
slev 2017), which will help us formulate implications for research
regarding cumulative meta-analysis that do not reach the required
information size (e.g. whether further trials are still necessary or are
superfluous to detect or reject a certain intervention effect). We will
conduct Trial Sequential Analysis using software from the Copen-
hagen Trial Unit (Thorlund 2011; TSA 2011).
‘Summary of findings’ tables
We will create ‘Summary of findings’ tables for the following clini-
cally relevant outcomes.
• All-cause mortality.
• Proportion of participants with clinically confirmed hepatitis A
infection (alanine transaminase (ALT) levels 2 to 3 times higher
than normal limit ≦ 43 mIU/L) (Kim 2008) and/or laboratory con-
firmed hepatitis A infection (Immunoglobulin M-HAV (IgM-HAV)).
• Proportion of participants with one or more serious adverse
events following immunisation with hepatitis A vaccines
• Health-related quality of life.
• Proportion of participants with adverse events considered to be
non-serious following immunisation with hepatitis A vaccines.
• Proportion of participants with anti-HAV antibody titre levels ≧
10 mIU/mL at the last study day available following vaccination.
We will report the longest follow-up with range of follow-up.
The GRADE approach appraises the 'certainty' (or 'quality') of a
body of evidence based on the extent to which one can be confident
that an estimate of effect or association reflects the item being as-
sessed. The certainty of a body of evidence includes consideration
of within-study risk of bias (methodological quality), indirectness of
the evidence (population, intervention, control, outcomes), unex-
plained heterogeneity or inconsistency of results (including prob-
lems with subgroup analyses); imprecision of effect estimates (e.g.
wide CIs), and a high probability of publication bias (Balshem 2011;
Mustafa 2013). We will define the levels of evidence as 'high', 'mod-
erate', 'low', or 'very low'. These grades are defined as follows.
• High certainty: we are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate certainty: we are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low certainty: our confidence in the effect estimate is limited:
the true effect may be substantially different from the estimate
of the effect.
• Very low certainty: we have very little confidence in the effect es-
timate: the true effect is likely to be substantially different from
the estimate of effect.
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A P P E N D I C E S
Appendix 1. Search strategy
 





Date will be given
at review stage
(hepatitis A OR hep A OR HAV) AND ((vaccine* AND (attenuated OR inactivated)) OR vac-






Latest issue #1 MeSH descriptor Vaccination explode all trees
#2 MeSH descriptor Immunization explode all trees
#3 ((vaccine* AND (attenuated OR inactivated)) OR vaccin* OR immuni* OR inoculat*)
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Hepatitis A explode all trees
#6 hepatitis A OR hep A OR HAV
#7 (#5 OR #6)
#8 (#4 AND #7)




3. ((vaccine* and (attenuated or inactivated)) or vaccin* or immuni* or inoculat*).mp.
[mp=title, abstract, original title, name of substance word, subject heading word, floating
sub-heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
4. 1 or 2 or 3
5. exp Hepatitis A/
6. (hepatitis A or hep A or HAV).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifi-
er, synonyms]
7. 5 or 6
8. 4 and 7
9. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original ti-
tle, name of substance word, subject heading word, floating sub-heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary con-
cept word, unique identifier, synonyms]
10. 8 and 9




3. ((vaccine* and (attenuated or inactivated)) or vaccin* or immuni* or inoculat*).mp.
[mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate
term word]
4. 1 or 2 or 3
5. exp hepatitis A/
6. (hepatitis A or hep A or HAV).mp. [mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword,
floating subheading word, candidate term word]
7. 5 or 6
8. 4 and 7
9. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading
word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword, floating subheading word, candidate term word]
10. 8 and 9
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LILACS (Bireme) 1982 to the date of
search
((vaccine$ AND (attenuated OR inactivated)) OR vaccin$ OR immuni$ OR inoculat$)




1900 to the date of
search
# 5 #4 AND #3
# 4 TS=(random* OR blind* OR placebo* OR meta-analys*)
# 3 #2 AND #1
# 2 TS=((vaccine* AND (attenuated OR inactivated)) OR vaccin* OR immuni* OR inoculat*)





1990 to the date of
search
# 5 #4 AND #3
# 4 TS=(random* OR blind* OR placebo* OR meta-analys*)
# 3 #2 AND #1
# 2 TS=((vaccine* AND (attenuated OR inactivated)) OR vaccin* OR immuni* OR inoculat*)
# 1 TS=(hepatitis A or hep A or HAV)
  (Continued)
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